Coronavirus disease was first diagnosed in December 2019, in the city of Wuhan, China. The World Health Organization recently declared coronavirus disease 2019 (COVID-19) as a pandemic. The infection is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a single-stranded RNA virus, which in humans causes mild respiratory symptoms and generally has a good prognosis. However, in a certain group of patients it manifests as severe pneumonia, respiratory distress syndrome, multiple organ dysfunction and death. The factors associated with a worse prognosis are older than 60 years, the presence of diabetes, cardiovascular disease and obesity. According to studies carried out in the Eastern world, the prevalence of liver injury in patients with COVID-19 disease varies between 14% and 53%, being more prevalent in patients with severe symptoms of COVID-19 disease. It is not really known whether the liver involvement of patients with SARS-CoV-2 infection is secondary to the direct effect of the virus on the liver. One of the mechanisms of action of SARS-CoV-2 is through the binding to the angiotensin-converting enzyme receptor, which is present in cholangiocytes, this could explain its excretion in faeces. However, liver injury could be due to the immune response generated in the body by the virus with systemic inflammatory response syndrome and the release of inflammatory cytokines such as IL6, generating direct cytopathic damage to the liver. On the other hand, it could be the product of hepatotoxic drugs administered during hospitalization, such as antibiotics, antivirals or non-steroidal anti-inflammatory drugs. Liver biopsy described microvacuolar steatosis, and a mild portal and lobular inflammatory infiltrate . Therefore, the aim this study is to assess the prevalence of liver complications (liver injury, decompensation of cirrhosis) in patients diagnosed with COVID-19 in Latin America. As secondary objectives, the investigators will describe the clinical characteristics of COVID-19 disease and identify risk factors associated with poor prognosis,
Scenario Multicenter study of patients hospitalized with SARS-CoV-2 in different institutions
in Latin America and directed by the Coronavirus and Liver interest group of the Latin
American Association for the Study of the Liver (ALEH), coordinated by Dr. Marcelo Silva.
This project has been presented to ALEH, which has considered it of high interest and will
promote its dissemination among partners and related Associations with the aim of obtaining
the greatest participation from the centers in the region.
Design Observational cross-sectional study to describe the prevalence of liver disease in
patients hospitalized for SARS-CoV-2. The administrative period of the study will be from
04/25/20 to 12/15/20. The enrollment date of the patients will be the date of the diagnosis
of SARS-CoV-2 infection and the date of end of follow-up will be the day of hospital
discharge, referral to another center or death.
Participating centers will identify patients who meet the selection criteria during the study
period. The diagnosis of SARS-CoV-2 can be made at any time during hospitalization. All
included patients will be evaluated and treated according to the specific protocol of each
institution. The follow-up period will run until the day of hospital discharge or death.
A specific coded form will be prepared for data registration, which will be subsequently
downloaded to a computerized database for subsequent analysis. The exposure variables
included in the form will be collected by the investigating doctors.
The following study will be performed following international recommendations for
observational studies STROBE guidelines
Other: Liver injury
LFTs elevation or liver decompensation
Inclusion Criteria:
- Patients older than 17 years
- Patients with diagnosis of SARS-CoV-2 infection
- Hospitalized patients
Exclusion Criteria:
-
Universidad Austral
Pilar, Buenos Aires, Argentina
Marcelo O Silva, MD, Principal Investigator
Austral University